Bayer stock weighs the September 14 court date.
Published on 08/25/2026 at 07:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bayer stock weighs the September 14 glyphosate hearing, and the company reported second-quarter 2026 revenue of EUR 10.872 billion, up 2.2 percent, with adjusted EBITDA of EUR 2.144 billion, up 1.9 percent, on August 24, 2026.
Legal date, hard numbers
The court date keeps litigation risk visible for Bayer (DE000BAY0017) even after management kept full-year 2026 guidance at EUR 44.7 billion to EUR 46.7 billion in revenue and EUR 4.20 to EUR 4.70 in core EPS. Core earnings per share in Q2 2026 fell 16.7 percent to EUR 0.95, while net income improved to EUR 219 million from a loss of EUR 199 million a year earlier.
Crop Science stood out in the quarter with revenue of EUR 4.910 billion, up 3.5 percent, and adjusted EBITDA of EUR 902 million, up 30.2 percent. Pharma posted revenue of EUR 4.458 billion, up 0.8 percent, and adjusted EBITDA of EUR 1.055 billion, showing a much calmer profile than the legal headline suggests.
Half-year backdrop
For the first half of 2026, Bayer reported revenue of EUR 24.277 billion, up 3.3 percent, and core EPS of EUR 3.66, up 3.4 percent. That comparison matters because it shows the second-quarter earnings base is not isolated: the company is still carrying growth into the year, even with a negative free cash flow of EUR 371 million in the quarter.
The balance-sheet target also moved in the right direction. Bayer now expects year-end net financial debt of EUR 29 billion to EUR 30 billion, compared with the earlier EUR 32 billion to EUR 33 billion range.
Drug pipeline context
A recent Japan clearance for Hyrnuo, Bayer's lung-cancer drug, adds a separate operating angle to the stock. The approval gives the oncology pipeline another commercial milestone while investors continue to weigh the legal calendar against the company’s reported 2026 operating momentum.
Trading view
On August 24, 2026, Bayer shares were quoted at EUR 47.78 on Tradegate, with a last closing price of EUR 48.04 and a year-to-date gain of 28.97 percent. The shares also traded between EUR 47.63 and EUR 48.08 intraday, leaving them below the 52-week high of EUR 53.92 but still well above the 52-week low of EUR 25.78.
More on Bayer stock
Investor relations
Company facts
Company: Bayer AG
ISIN: DE000BAY0017
Ticker: BAYN
Exchange: Xetra
Price (as of August 24, 2026, 4:00 p.m. ET): EUR 47.78
Market cap: EUR 46.85 billion
Sector / Industry: Health Care / Pharmaceuticals
Index membership: DAX
